{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:21:54Z","timestamp":1787066514767,"version":"build-2736575974"},"reference-count":19,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Precision medicine has transformed how we manage cancer patients. As treatments and drug targets become more complex, the associated diagnostic technologies must also evolve to actualize the benefit of these therapeutic innovations. Digital and computational pathology (DP\/CP) play a pivotal role in this evolution, offering enhanced analytical techniques and addressing workflow constraints in pathology labs. This study aims to understand clinicians\u2019 awareness, utilization, and willingness to adopt DP\/CP-based tools, as well as the role they perceive themselves playing in the adoption of CP-based tests. Methods: A double-blinded, online quantitative survey was conducted among 101 U.S.-based medical oncologists. Results: Awareness of DP\/CP varied among clinicians, with only 17% identifying as very aware. Subsequently, the current utilization of CP-based tests is also low. Despite this, clinicians are optimistic about the potential benefits of DP\/CP, including reduced turnaround times, improved therapy selection, and more consistent slide review. To achieve full adoption, clinicians recognize that barriers must be addressed, including cost, regulatory guidance and, to a lesser extent, concerns with the \u201cblack box\u201d nature of CP algorithms. While the focus for the adoption of DP has centered on pathologists, clinicians anticipate playing a more significant role in the adoption of CP-based tests. Finally, clinicians demonstrated clear willingness to utilize a CP-based CDx, with 90% of respondents identifying as potential adopters. Conclusions: This study highlights a positive outlook for the adoption of DP\/CP among clinicians, despite varied awareness and low current utilization. Clinicians recognize the potential benefits of DP\/CP but also acknowledge barriers to adoption. Addressing these barriers through education, regulatory approval, and collaboration with pathologists and biopharma is essential for successfully integrating DP\/CP technologies into clinical practice.<\/jats:p>","DOI":"10.3390\/diagnostics15192527","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:46:56Z","timestamp":1759841216000},"page":"2527","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinician Perspectives on Digital and Computational Pathology: Clinical Benefits, Concerns, and Willingness to Adopt"],"prefix":"10.3390","volume":"15","author":[{"given":"Charu","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McConnell","sequence":"additional","affiliation":[{"name":"Health Advances LLC, 275 Grove St. Ste 1-300, Auburndale, MA 02466, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cadirov","sequence":"additional","affiliation":[{"name":"Health Advances LLC, 275 Grove St. Ste 1-300, Auburndale, MA 02466, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-6062","authenticated-orcid":false,"given":"Gary","family":"Gustavsen","sequence":"additional","affiliation":[{"name":"Health Advances LLC, 275 Grove St. Ste 1-300, Auburndale, MA 02466, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Health Advances LLC, 275 Grove St. Ste 1-300, Auburndale, MA 02466, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Chehab","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Kotapati","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikunj","family":"Patel","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5858\/arpa.2015-0453-RA","article-title":"Immunohistochemistry as a Practical Tool in Molecular Pathology","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13000-024-01590-2","article-title":"The current troubled state of the global pathology workforce: A concise review","volume":"19","author":"Walsh","year":"2024","journal-title":"Diagn. Pathol."},{"key":"ref_3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liao, J., Li, X., Gan, Y., Han, S., Rong, P., Wang, W., Li, W., and Zhou, L. (2023). Artificial intelligence assists precision medicine in cancer treatment. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.998222"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, Y.-M., Hsiao, T.-H., Lin, C.-H., and Fann, Y.C. (2025). Unlocking precision medicine: Clinical applications of integrating health records, genetics, and immunology through artificial intelligence. J. Biomed. Sci., 32.","DOI":"10.1186\/s12929-024-01110-w"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S1470-2045(19)30154-8","article-title":"Digital pathology and artificial intelligence","volume":"20","author":"Niazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology\u2014New tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s10278-020-00351-z","article-title":"Whole Slide Imaging (WSI) in Pathology: Current Perspectives and Future Directions","volume":"33","author":"Kumar","year":"2020","journal-title":"J. Digit. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41379-021-00919-2","article-title":"Digital pathology and artificial intelligence in translational medicine and clinical practice","volume":"35","author":"Baxi","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.5966","article-title":"The state of the art for artificial intelligence in lung digital pathology","volume":"257","author":"Viswanathan","year":"2022","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13000-024-01453-w","article-title":"Artificial intelligence\u2019s impact on breast cancer pathology: A literature review","volume":"19","author":"Soliman","year":"2024","journal-title":"Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00428-021-03213-3","article-title":"Artificial intelligence applied to breast pathology","volume":"480","author":"Yousif","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bayramoglu, N., Kaakinen, M., Eklund, L., and Heikkil\u00e4, J. (2017, January 22\u201329). Towards Virtual H&E Staining of Hyperspectral Lung Histology Images Using Conditional Generative Adversarial Networks. Proceedings of the 2017 IEEE International Conference on Computer Vision Workshops (ICCVW), Venice, Italy.","DOI":"10.1109\/ICCVW.2017.15"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kapil, A., Spitzm\u00fcller, A., Brieu, N., Haneder, S., Shumilov, A., Meier, A., Cecchi, F., Barkell, A., Harder, N., and Mittermaier, K. (2024). HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-61957-9"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.modpat.2022.100033","article-title":"Noninferiority of Artificial Intelligence\u2013Assisted Analysis of Ki-67 and Estrogen\/Progesterone Receptor in Breast Cancer Routine Diagnostics","volume":"36","author":"Abele","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Xia, D., Casanova, R., Machiraju, D., McKee, T.D., Weder, W., Beck, A.H., and Soltermann, A. (2018). Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-22254-4"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2025.43.16_suppl.8501","article-title":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)","volume":"43","author":"Levy","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Schroll, M.M., Quinn, E., Pritchard, D., Chang, A., Garner Amanti, K., Perez, O., Agarwal, A., and Gustavsen, G. (2024). Perspectives on Clinical Adoption Barriers to Blood-Based Multi-Cancer Early Detection Tests across Stakeholders. J. Pers. Med., 14.","DOI":"10.3390\/jpm14060593"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/19\/2527\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:04Z","timestamp":1760035804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/19\/2527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":19,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["diagnostics15192527"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15192527","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}